DoorDash Q2 Revenue Jumps 36% as Orders and DashPass Growth Drive Results 
Berkshire Hathaway Cash Falls as Abel Boosts Stock Buybacks 
SanDisk Q4 Earnings Beat Estimates as Q1 Revenue Outlook Meets Expectations 
Qantas Shares Climb as Long-Haul Pilot Deal Eases Strike Concerns 
DBS Raises 2025 Outlook After Record Q2 Profit Driven by Wealth Management 
AMP Shares Surge 13% After Strong Profit and A$150 Million Buyback 
Mercedes-Benz Stock Offers Deep-Value Potential as Citi Sees Recovery Catalysts 
Nvidia to Invest Up to $3 Billion in Blackstone-Backed Lancium 
Western Digital Q4 Earnings Beat Estimates as FY2027 Outlook Tops Expectations 
DeepSeek to Raise AI API Prices as Demand for New Models Surges 
Cloudflare Stock Jumps 15% as Earnings Beat Estimates, 2026 Outlook Raised 
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback 
OpenAI Restricts Astra AI Over Cyberattack Risks 
Glencore Posts Strong H1 2026 Earnings, Announces ASX Secondary Listing 
Meta Ordered to Pay $567M Over Child Safety Violations in New Mexico 
Shein Scales Back Vietnam Operations as US Trade Rules Shift 
NEW YORK and MELBOURNE, Australia, Feb. 26, 2018 -- Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) today announced it will report financial results for the first half year ended December 31, 2017 in a webcast beginning at 4:30 pm EST on Tuesday, February 27, 2018; 8:30 am Wednesday, February 28, 2018 AEDT.
The live webcast can be accessed via
http://webcasting.brrmedia.com/broadcast/5a6ffa22271b41638bdc2f22
To access the call only, dial 1 855 881 1339 (U.S.), 1 800 558 698 (toll-free Australia) or +61 2 9007 3187 (outside of the U.S. and Australia). The conference identification code is 882151.
The archived webcast will be available on the Investor page of the Company’s website – www.mesoblast.com
About Mesoblast
Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) is a global leader in developing innovative cell-based medicines. The Company has leveraged its proprietary technology platform, which is based on specialized cells known as mesenchymal lineage adult stem cells, to establish a broad portfolio of late-stage product candidates. Mesoblast’s allogeneic, ‘off-the-shelf’ cell product candidates target advanced stages of diseases with high, unmet medical needs including cardiovascular diseases, immune-mediated and inflammatory disorders, orthopedic disorders, and oncologic/hematologic conditions.
For further information, please contact:
Julie Meldrum
Corporate Communications
Mesoblast Limited
T: +61 3 9639 6036
E: [email protected]
Schond Greenway
Investor Relations
Mesoblast Limited
T: +1 212 880 2060
E: [email protected]
